.jpeg)
r-hFSH
Category: Articles
In Date: Monday, May 13, 2024
No views
study time: ۱۰ MinutesRecombinant Human Follicle-Stimulating Hormone (r-hFSH)
Recombinant human follicle-stimulating hormone (r-hFSH) is an important advancement in reproductive medicine. Produced through recombinant DNA technology, r-hFSH plays a key role in fertility treatments by supporting ovarian follicular development and controlled ovarian stimulation.
What you read in this article:
- What Is Recombinant FSH?
- How Does r-hFSH Work?
- Clinical Applications of r-hFSH
- Benefits and Safety Considerations
What Is Recombinant FSH?
Follicle-stimulating hormone (FSH) is a naturally occurring hormone produced by the pituitary gland that regulates reproductive function in both women and men.
Recombinant FSH is manufactured using biotechnology rather than being extracted from human urine. This production method enables controlled manufacturing processes, consistent product quality, and precise dosing.
How Does r-hFSH Work?
In women, r-hFSH binds to FSH receptors on ovarian granulosa cells, stimulating follicular growth and supporting estrogen production.
During fertility treatment, r-hFSH promotes the development of ovarian follicles, allowing multiple oocytes to mature as part of controlled ovarian stimulation protocols.
The dose and duration of treatment are individualized according to ovarian reserve, treatment response, and clinical assessment.
Clinical Applications of r-hFSH
Recombinant FSH is widely used in reproductive medicine for several indications:
- Assisted Reproductive Technologies (ART): Stimulates the development of multiple follicles during IVF and ICSI treatment cycles.
- Ovulation Induction: Supports follicular development in selected women with anovulatory infertility.
- Male Infertility: In certain men with hypogonadotropic hypogonadism, r-hFSH may be administered alongside hCG to stimulate sperm production.
Benefits and Safety Considerations
Recombinant DNA technology allows the production of FSH with controlled purity and consistent manufacturing quality.
Prefilled injection pens can also support accurate dose selection and convenient subcutaneous administration.
However, treatment requires appropriate medical supervision. Ovarian response is typically monitored through ultrasound examinations and, when indicated, hormonal assessments to optimize treatment and reduce the risk of ovarian hyperstimulation syndrome (OHSS).
Conclusion
Recombinant FSH has become an established component of modern fertility treatment. By combining biotechnology with individualized ovarian stimulation protocols, r-hFSH provides a reliable therapeutic option for patients undergoing assisted reproductive treatment.
This article is intended for educational purposes. Treatment decisions should be made under the supervision of a qualified fertility specialist.


